On June 8, 2023, Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, announced the completion of a $200 million Series B financing. The Series B round was led jointly by Enavate Sciences and Venrock Healthcare Capital Partners, with participation from other new investors Bain Capital Life Sciences and Wellington Management and Series A investors OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds, and Samsara BioCapital.

Wilson Sonsini Goodrich & Rosati advised Venrock Healthcare Capital Partners on IP matters related to the transaction. The Wilson Sonsini team was led by Laurie McNamara and included Yingchun Ni, Matthew Garnica, Jane Yang, Yugong Cheng, and Mike Hostetler.

For more information, please see the press release.